Difference between revisions of "Team:Amoy/Description"

 
(28 intermediate revisions by 6 users not shown)
Line 10: Line 10:
  
 
<link rel="stylesheet" type="text/css" href="https://2015.igem.org/Template:Amoy/css/MenuBarCss?action=raw&amp;ctype=text/css" />
 
<link rel="stylesheet" type="text/css" href="https://2015.igem.org/Template:Amoy/css/MenuBarCss?action=raw&amp;ctype=text/css" />
 +
 +
<link rel="stylesheet" type="text/css" href="https://2015.igem.org/Template:Amoy/css/MenuCss?action=raw&amp;ctype=text/css" />
 +
 +
<script type="text/javascript" src="https://2015.igem.org/Template:Amoy/Javascript/MenuJs?action=raw&amp;ctype=text/javascript"></script>
  
 
</head>
 
</head>
Line 44: Line 48:
  
 
<!--top_menu-->
 
<!--top_menu-->
<div id='cssmenu'>
+
<span class="preload1"></span> <span class="preload2"></span>
<ul>
+
<ul id="nav">
  <li class='has-sub'><a href='https://2015.igem.org/Team:Amoy/Team'>Team</a>
+
  <li class="top"><a href="https://2015.igem.org/Team:Amoy/Team" id="products" class="top_link"><span class="down">TEAM</span></a>
      <ul>
+
    <ul class="sub">
        <li class='has-sub'><a href='https://2015.igem.org/Team:Amoy/Team#member_student'>Member</a></li>
+
      <li><a href="https://2015.igem.org/Team:Amoy/Team#member_student">Member</a></li>
        <li class='has-sub'><a href='https://2015.igem.org/Team:Amoy/Member/Amoy'>Amoy</a></li>
+
       <li><a href="https://2015.igem.org/Team:Amoy/Member/Amoy">Amoy</a></li>
        <li class='has-sub'><a href='https://2015.igem.org/Team:Amoy/Attributions'>Attributions</a></li>
+
      <li><a href="https://2015.igem.org/Team:Amoy/Attributions">Attributions</a></li>
      </ul>
+
    </ul>
  </li>
+
  </li>
  <li class='active has-sub'><a href='https://2015.igem.org/Team:Amoy/Project'>Project</a>
+
      <ul>
+
        <li class='has-sub'><a href='https://2015.igem.org/Team:Amoy/Description'>Description</a></li>
+
        <li class='has-sub'><a href='https://2015.igem.org/Team:Amoy/Project/Background'>Background</a></li>
+
        <li class='has-sub'><a href='https://2015.igem.org/Team:Amoy/Project/Methods'>Methods</a></li>
+
        <li class='has-sub'><a href='https://2015.igem.org/Team:Amoy/Project/Results'>Results</a></li>
+
        <li class='has-sub'><a href='https://2015.igem.org/Team:Amoy/Project/Discussion'>Discussion</a></li>
+
        <li class='has-sub'><a href='https://2015.igem.org/Team:Amoy/Project/FutureWork'>Future Work</a></li>
+
       </ul>
+
  </li>
+
  <li class='has-sub'><a href='https://2015.igem.org/Team:Amoy/Notebook'>Notebook</a>
+
      <ul>
+
        <li class='has-sub'><a href='https://2015.igem.org/Team:Amoy/Notebook/Notebook'>Notebook</a></li>
+
        <li class='has-sub'><a href='https://2015.igem.org/Team:Amoy/Notebook/Protocol'>Protocols</a></li>
+
        <li class='has-sub'><a href='https://2015.igem.org/Team:Amoy/Parts'>Parts</a></li>
+
        <li class='has-sub'><a href='https://2015.igem.org/Team:Amoy/Notebook/Gallery'>Gallery</a></li>
+
      </ul>
+
  </li>
+
  <li><a href='https://2015.igem.org/Team:Amoy/Interlab' style="margin-right: 30px; margin-left: 10px;">Interlab</a></li>
+
  
  <li class='has-sub'><a href='https://2015.igem.org/Team:Amoy/Newsletter'>Newsletter</a>
+
  <li class="top"><a href="https://2015.igem.org/Team:Amoy/Project" id="products" class="top_link"><span class="down active">PROJECT</span></a>
       <ul>
+
    <ul class="sub">
        <li class='has-sub'><a href='https://2015.igem.org/Team:Amoy/Newsletter#title'>Introduction</a></li>
+
      <li><a href="https://2015.igem.org/Team:Amoy/Project/Background">Background</a></li>
        <li class='has-sub'><a href='https://2015.igem.org/Team:Amoy/Newsletter/Contribution'>Contribution</a></li>
+
       <li><a href="https://2015.igem.org/Team:Amoy/Description">Description</a></li>
        <li class='has-sub'><a href='https://2015.igem.org/Team:Amoy/Newsletter/Discussion'>Discussion</a></li>
+
      <li><a href="https://2015.igem.org/Team:Amoy/Project/Methods">Methods</a></li>
        <li class='has-sub'><a href='https://2015.igem.org/Team:Amoy/Newsletter/Links'>Links</a></li>
+
      <li><a href="https://2015.igem.org/Team:Amoy/Project/Results">Results</a></li>
      </ul>
+
      <li><a href="https://2015.igem.org/Team:Amoy/Project/Discussion">Discussion</a></li>
  </li>
+
      <li><a href="https://2015.igem.org/Team:Amoy/Project/FutureWork">Future Work</a></li>
  <li class='has-sub'><a href='https://2015.igem.org/Team:Amoy/Practices'>Practices</a>
+
    </ul>
      <ul>
+
  </li>
        <li class='has-sub'><a href='https://2015.igem.org/Team:Amoy/Practices/Promotion'>Promotion</a></li>
+
 
        <li class='has-sub'><a href='https://2015.igem.org/Team:Amoy/Practices/Talk'>Talk</a></li>
+
  <li class="top"><a href="https://2015.igem.org/Team:Amoy/Notebook" id="products" class="top_link"><span class="down">NOTEBOOK</span></a>
        <li class='has-sub'><a href='https://2015.igem.org/Team:Amoy/Practice/Communication'>Communication</a></li>
+
    <ul class="sub">
        <li class='has-sub'><a href='https://2015.igem.org/Team:Amoy/Collaborations'>Collaborations</a></li>
+
      <li><a href="https://2015.igem.org/Team:Amoy/Notebook/Notebook">Notebook</a></li>
      </ul>
+
      <li><a href="https://2015.igem.org/Team:Amoy/Notebook/Protocol">Protocols</a></li>
  </li>
+
      <li><a href="https://2015.igem.org/Team:Amoy/Parts">Parts</a></li>
  <li class='has-sub'><a href='https://2015.igem.org/Team:Amoy/Judging'>Judging</a>
+
      <li><a href="https://2015.igem.org/Team:Amoy/Notebook/Gallery">Gallery</a></li>
      <ul>
+
    </ul>
        <li class='has-sub'><a href='https://2015.igem.org/Team:Amoy/Judging/Medal'>Medal Criteria</a></li>
+
  </li>
        <li class='has-sub'><a href='https://2015.igem.org/Team:Amoy/Judging/Acknowledgement'>Acknowledgement</a></li>
+
 
      </ul>
+
  <li class="top"><a href="https://2015.igem.org/Team:Amoy/Interlab" id="products" class="top_link"><span class="down">INTERLAB</span></a></li>
  </li>
+
 
  <li><a href='https://2015.igem.org/Team:Amoy/Safety'>Safety</a></li>
+
  <li class="top"><a href="https://2015.igem.org/Team:Amoy/Newsletter" id="products" class="top_link"><span class="down">NEWSLETTER</span></a>
 +
    <ul class="sub">
 +
      <li><a href="https://2015.igem.org/Team:Amoy/Newsletter#title">Introduction</a></li>
 +
      <li><a href="https://2015.igem.org/Team:Amoy/Newsletter/Contribution">Contribution</a></li>
 +
      <li><a href="https://2015.igem.org/Team:Amoy/Newsletter/Discussion">Discussion</a></li>
 +
      <li><a href="https://2015.igem.org/Team:Amoy/Newsletter/Links">Links</a></li>
 +
    </ul>
 +
  </li>
 +
 
 +
  <li class="top"><a href="https://2015.igem.org/Team:Amoy/Practices" id="products" class="top_link"><span class="down">PRACTICES</span></a>
 +
    <ul class="sub">
 +
      <li><a href="https://2015.igem.org/Team:Amoy/Practices/Promotion">Promotion</a></li>
 +
      <li><a href="https://2015.igem.org/Team:Amoy/Practices/Talk">Talk</a></li>
 +
      <li><a href="https://2015.igem.org/Team:Amoy/Practice/Communication">Communication</a></li>
 +
      <li><a href="https://2015.igem.org/Team:Amoy/Collaborations">Collaborations</a></li>
 +
    </ul>
 +
  </li>
 +
 
 +
  <li class="top"><a href="https://2015.igem.org/Team:Amoy/Judging" id="products" class="top_link"><span class="down">JUDGING</span></a>
 +
    <ul class="sub">
 +
      <li><a href="https://2015.igem.org/Team:Amoy/Judging/Medal">Medal Criteria</a></li>
 +
      <li><a href="https://2015.igem.org/Team:Amoy/Judging/Acknowledgement">Acknowledgement</a></li>
 +
    </ul>
 +
  </li>
 +
 
 +
  <li class="top"><a href="https://2015.igem.org/Team:Amoy/Safety" id="products" class="top_link"><span class="down">SAFETY</span></a></li>
 
</ul>
 
</ul>
</div>
 
  
 
</div>
 
</div>
 +
  
  
Line 109: Line 119:
 
<a href="https://2015.igem.org/Team:Amoy/Project"><h4>Project</h4></a>
 
<a href="https://2015.igem.org/Team:Amoy/Project"><h4>Project</h4></a>
 
<ul class="ul_menu">
 
<ul class="ul_menu">
<li><a href="https://2015.igem.org/Team:Amoy/Description">Description</a></li>
 
 
<li><a href="https://2015.igem.org/Team:Amoy/Project/Background">Background</a></li>
 
<li><a href="https://2015.igem.org/Team:Amoy/Project/Background">Background</a></li>
 +
<li><a href="https://2015.igem.org/Team:Amoy/Description">Description</a></li>
 
<li><a href="https://2015.igem.org/Team:Amoy/Project/Methods">Methods</a></li>
 
<li><a href="https://2015.igem.org/Team:Amoy/Project/Methods">Methods</a></li>
 
<li><a href="https://2015.igem.org/Team:Amoy/Project/Results">Results</a></li>
 
<li><a href="https://2015.igem.org/Team:Amoy/Project/Results">Results</a></li>
Line 121: Line 131:
 
<div id="title" style="width: 70%; margin-left: 25%;">
 
<div id="title" style="width: 70%; margin-left: 25%;">
 
<p id="title_p">DESCIPTION</p>
 
<p id="title_p">DESCIPTION</p>
<p class="main_p">L-<i>tert</i>-leucine is an unnatural amino acid which plays an important role in various industrial products, especially in pharmaceuticals. Due to the specific steric hindrance of its side chain, L-<i>tert</i>-leucine is important in asymmetric synthesis. It is also an indispensable intermediate to synthesis drugs such as Atazanavir. Atazanavir is one of the most effective HIV-protease inhibitor confirmed by FDA. As we all know, AIDs is an awful disease which has disturbed human for many years. Lots of people suffered from ADIS and died in pain. To synthesis L-<i>tert</i>-leucine with high chiral selectivity on a large scale is still a challenge for human. </br></p>
+
<p class="main_p">L-<i>tert</i>-leucine is an unnatural amino acid which plays an important role in various industrial products, especially in pharmaceuticals. </br></br>
  
<img class="main_img" src="https://static.igem.org/mediawiki/2015/3/39/Amoy-Project_Description_fig1.png" style="width: 50%;" />
+
With its application, many methods were developed for its preparation in the past decades. Some of them have low conversion rate and poor chiral selectivity.Thirty years ago, scientists developed enzymatic reductive amination to produce L-<i>tert</i>-leucine by using leucine dehydrogenase and formate dehydrogenase. This technology greatly improved the yield and excellent enantiomeric excess value of L-<i>tert</i>-leucine. It is regarded to be one of the most efficient routes. But due to the different activity of leucine dehydrogenase and format dehydrogenase, this method is not perfect(Figuer 1) [1]. The cofactor regeneration may be broken in reaction processes.</br></p>
  
<p class="figure" style="text-align: center; margin-top: 20px; width: 80%;"><strong>Figure 1</strong> The structure of L-tert-leucine</p>
+
<img class="main_img" src="https://static.igem.org/mediawiki/2015/b/bd/Amoy-Project_Description_fig4.png" style="width: 100%;" />
  
<p class="main_p"></br></br>With its importance, many methodologies were developed for its preparation in the past decades. Scientists have developed enzymatic reductive amination to produce L-<i>tert</i>-leucine by using leucine dehydrogenase and formate dehydrogenase. This technology greatly improved the yield and excellent enantiomeric excess of L-<i>tert</i>-leucine. It is regarded to be one of the most efficient routes.</br></p>
+
<p class="figure" style="text-align: center; margin-top: 20px;"><strong>Figure 1</strong> The enzymatic reductive amination for synthesizing L-<i>tert</i>-leucine and the bug of this method</p>  
  
<img class="main_img" src="https://static.igem.org/mediawiki/2015/0/02/Amoy-Project_Description_fig2.png" style="width: 50%;" />
+
<p class="main_p"></br></br>In order to solve this problem, we put forward many methods. The basic idea is variable control. We constructed plasmids which bear leucine dehydrogenase gene (<i>leudh</i>) and formate dehydrogenase gene (<i>fdh</i>). One plasmid which contains both leucine dehydrogenase gene and format dehydrogenase gene controls the copy numbers and the transformation efficiency. And the only variable is efficiency of ribosome binding sites or strength of promoters. So the first method is changing different ribosome binding sites. Because of the weak activity of formate dehydrogenase, we connected <i>fdh</i> with the strongest ribosome binding site from iGEM registry, which is numbered BBa_B0034. Then, we changed the ribosome binding site of <i>leudh</i>(Figure 2) [2]. 
 +
</br></p>
  
<p class="figure" style="text-align: center; margin-top: 20px;"><strong>Figure 2</strong> The synthesis of L-tert-leucine</p>
+
<img class="main_img" src="https://static.igem.org/mediawiki/2015/7/7b/Amoy-Project_Description_figure21.png" style="width: 100%;" />
  
<p class="main_p"></br></br>To optimize this circle, we have tried many methods. Finally we constructed one genetic circuit containing two target genes and use whole-cell catalysts. There are several advantages using this method. Firstly, none or only very little external cofactor is required, because it is already contained in the whole-cell biocatalyst with the help of cofactor regeneration. Secondly, only one fermentation is required to produce the biocatalyst compared to two separate fermentations to clone cells containing LeuDH and FDH respectively, which is much more convenient. What’s more the biocatalyst is suitable for high-cell density fermentations. No isolation or purification of enzymes are required so that the cost become lower. Last but not least, whole-cell catalysts can achieve the effect of premix, which help to make the two enzymes cooperate well. In a word, the method we adopt not only can lower the cost but also makes it easy for us to adjust the expression level of the two target genes.</br></p>
+
<p class="figure" style="text-align: center; margin-top: 20px;"><strong>Figure 2</strong> Method 1: changing ribosome binding site to regulate the activity of leucine dehydrogenase</p>
  
<img class="main_img" src="https://static.igem.org/mediawiki/2015/0/0f/Amoy-Project_Description_fig3.png" style="width: 100%;" />
+
<p class="main_p"></br></br>Optimizing L-<i>tert</i>-leucine synthesis by changing the promoter is an alternative method. Promoter is also an important factor of translation process. So the second method is changing different promoters and finding out the optimal promoter.</br></br>
  
<p class="figure" style="text-align: center; margin-top: 20px;"><strong>Figure 3</strong> The circuit constructed</p>
+
However, the parts of different ribosome binding sites and promoters which we got from the iGEM authority cannot meet our demands, because these parts are not continuously adjustable. That means we may not be able to get optimal RBS or promoter for <i>leudh</i>. However, we were illuminated by the project did by Peking University in 2011. We get the idea that we could use genetic rheostats as RBS regulators. Then, we could get the excellent RBS efficiency and use RBS calculators to edit the RBSs' sequence to a suitable efficiency(Figure 3) [3,4].</br></p>
 
+
<p class="main_p"></br></br>However, owing to different activity of leucine dehydrogenase and formate dehydrogenase, the NADH consumption rate does not equal to its regeneration. Therefore, it is necessary to add excess NADH. The cofactor-NADH is a pretty expensive raw material, which will make the mass production of L-<i>tert</i>-leucine not cost-effective.</br></p>
+
 
+
<img class="main_img" src="https://static.igem.org/mediawiki/2015/b/bd/Amoy-Project_Description_fig4.png" style="width: 100%;" />
+
  
<p class="figure" style="text-align: center; margin-top: 20px;"><strong>Figure 4</strong> Different activities of leucine dehydrogenase and formate dehydrogenase</p>
+
<img class="main_img" src="https://static.igem.org/mediawiki/2015/3/3f/Amoy-Project_Description_figure31.png" style="width: 100%;" />
  
<p class="main_p"></br></br>The whole plan is to regulate the efficiency of ribosome binding site. In other words, RBS, to control the strength of LeuDH and FDH. With the help of mathematical modeling, the most suitable efficiency of RBS of leucine dehydrogenase will be obtained. Consequently, the co-factor NADH can be self-sufficient as shown in this cycle. We have investigated a lot of RBS and try to choose the most probable pair of RBS and we choose B0032、B0030 and B0034 for plasmid construction. Through this way, it is no hard work to control RBS strength in one circuit.</br></p>
+
<p class="figure" style="text-align: center; margin-top: 20px;"><strong>Figure 3</strong> Method 3: Using genetic rheostat to regulate the activity of leucine dehydrogenase </p>
  
 +
<h1 class="main_h1">Reference:</h1>
  
 +
<p class="main_p">[1] Li, J., Pan, J., Zhang, J. & Xu, H., J. Stereoselective synthesis of L-<i>tert</i>-leucine by a newly cloned leucine dehydrogenase from Exiguobacterium sibiricum. <i>J. Mol. Catal. B-Enzym</i>. <strong>105</strong>, 11-17 (2014)</br>
 +
[2] <a href="https://2010.igem.org/Team:Warsaw/Stage1"> http://https://2010.igem.org/Team:Warsaw/Stage1</a></br>
 +
[3] <a href="https://2011.igem.org/Team:Peking_R/Project/RNAToolkit"> https://2011.igem.org/Team:Peking_R/Project/RNAToolkit</a></br>
 +
[4] Reeve, B., Hargest, T., Gilbert, C. & Ellis T. Predicting translation initiation rates for designing synthetic biology. <i>Mini Review Article</i>. <strong>2</strong>, 1-6 (2014)
 +
</p>
 
</div>
 
</div>
 
<!--end_ main-->
 
<!--end_ main-->

Latest revision as of 03:00, 19 September 2015

Aomy/Project

DESCIPTION

L-tert-leucine is an unnatural amino acid which plays an important role in various industrial products, especially in pharmaceuticals.

With its application, many methods were developed for its preparation in the past decades. Some of them have low conversion rate and poor chiral selectivity.Thirty years ago, scientists developed enzymatic reductive amination to produce L-tert-leucine by using leucine dehydrogenase and formate dehydrogenase. This technology greatly improved the yield and excellent enantiomeric excess value of L-tert-leucine. It is regarded to be one of the most efficient routes. But due to the different activity of leucine dehydrogenase and format dehydrogenase, this method is not perfect(Figuer 1) [1]. The cofactor regeneration may be broken in reaction processes.

Figure 1 The enzymatic reductive amination for synthesizing L-tert-leucine and the bug of this method



In order to solve this problem, we put forward many methods. The basic idea is variable control. We constructed plasmids which bear leucine dehydrogenase gene (leudh) and formate dehydrogenase gene (fdh). One plasmid which contains both leucine dehydrogenase gene and format dehydrogenase gene controls the copy numbers and the transformation efficiency. And the only variable is efficiency of ribosome binding sites or strength of promoters. So the first method is changing different ribosome binding sites. Because of the weak activity of formate dehydrogenase, we connected fdh with the strongest ribosome binding site from iGEM registry, which is numbered BBa_B0034. Then, we changed the ribosome binding site of leudh(Figure 2) [2].

Figure 2 Method 1: changing ribosome binding site to regulate the activity of leucine dehydrogenase



Optimizing L-tert-leucine synthesis by changing the promoter is an alternative method. Promoter is also an important factor of translation process. So the second method is changing different promoters and finding out the optimal promoter.

However, the parts of different ribosome binding sites and promoters which we got from the iGEM authority cannot meet our demands, because these parts are not continuously adjustable. That means we may not be able to get optimal RBS or promoter for leudh. However, we were illuminated by the project did by Peking University in 2011. We get the idea that we could use genetic rheostats as RBS regulators. Then, we could get the excellent RBS efficiency and use RBS calculators to edit the RBSs' sequence to a suitable efficiency(Figure 3) [3,4].

Figure 3 Method 3: Using genetic rheostat to regulate the activity of leucine dehydrogenase

Reference:

[1] Li, J., Pan, J., Zhang, J. & Xu, H., J. Stereoselective synthesis of L-tert-leucine by a newly cloned leucine dehydrogenase from Exiguobacterium sibiricum. J. Mol. Catal. B-Enzym. 105, 11-17 (2014)
[2] http://https://2010.igem.org/Team:Warsaw/Stage1
[3] https://2011.igem.org/Team:Peking_R/Project/RNAToolkit
[4] Reeve, B., Hargest, T., Gilbert, C. & Ellis T. Predicting translation initiation rates for designing synthetic biology. Mini Review Article. 2, 1-6 (2014)

CONTACT US

Email: igemxmu@gmail.com

Website: 2015.igem.org/Team:Amoy

Address: Xiamen University, No. 422, Siming South Road, Xiamen, Fujian, P.R.China 361005